PLUS1
Best deals to access real time data! |
|
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
|
|
DDE w/Realtime (Monthly)
Monthly Subscription
for only
|
|
Big Cap Pro
Monthly Subscription
for only
|
|
VAT not included
|
|
After Hours Last Trade |
Last $ 49.49 ▲ 0.74 (1.52%) | |
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Axsome Therapeutics Inc | AXSM | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | High Price | Low Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| 3.62 | 8.02% | 48.75 | 49.30 | 45.46 | 45.46 | 45.13 | 20:00:00 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 48.88 | 49.50 | 0.62 | 1.25% | - | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 15,327 | 1,591,371 | $ 48.17 | $ 76,650,552 | 1,037,509 | 1.94 - 49.50 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 19:56:26 | 50 | $ 49.46 | USD |
Axsome Therapeutics Financials
| Market Cap | Shares in Issue | Profit/Loss | Earnings Per Share (EPS) | PE Ratio | Float |
|---|---|---|---|---|---|
| $ 1.68B | 34.51M | $ -30.97M | -1.14 | - | 33.72M |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | 5.00 | 2.30% |
Axsome Therapeutics News
| Date | Time | Source | News Article |
|---|---|---|---|
| 12/03/2019 | 06:00 | GlobeNewswire Inc. | Axsome Therapeutics Announces AXS-12 Achieves Primary.. |
| 11/21/2019 | 07:00 | GlobeNewswire Inc. | Axsome Therapeutics to Host Investor R&D Call with Key.. |
| 11/07/2019 | 17:08 | Edgar (US Regulatory) | Quarterly Report (10-q) |
| 11/07/2019 | 16:54 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 11/07/2019 | 07:19 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 11/07/2019 | 07:00 | GlobeNewswire Inc. | Axsome Therapeutics Reports Third Quarter 2019 Financial.. |
| 10/29/2019 | 07:00 | GlobeNewswire Inc. | Axsome Therapeutics to Report Third Quarter 2019 Financial.. |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical AXSM Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 45.13 | 49.50 | 40.55 | 45.35 | 1,743,997 | 3.62 | 8.02% |
| 1 Month | 25.11 | 49.50 | 24.15 | 37.52 | 1,239,581 | 23.64 | 94.15% |
| 3 Months | 29.28 | 49.50 | 13.64 | 26.84 | 1,096,076 | 19.47 | 66.5% |
| 6 Months | 22.07 | 49.50 | 13.64 | 26.07 | 928,152 | 26.68 | 120.89% |
| 1 Year | 3.50 | 49.50 | 1.94 | 16.64 | 1,358,437 | 45.25 | 1,292.86% |
| 3 Years | 6.60 | 49.50 | 1.94 | 13.66 | 593,963 | 42.15 | 638.64% |
| 5 Years | 9.00 | 49.50 | 1.94 | 13.56 | 447,392 | 39.75 | 441.67% |
Axsome Therapeutics Description
| Axsome Therapeutics Inc is a United States-based healthcare service provider. As a pre-clinical therapeutics developer, the company attends primarily to central nervous system disorders such as Alzheimer's. Its product portfolio consists of novel drugs like the AXS-02 (disodium zoledronate tetrahydrate), which is an oral, non-opioid therapeutic for chronic pain and the AXS-05, which is a fixed-dose combination of dextromethorphan and bupropion. The AXS-02 addresses pain in over three conditions, such as complex regional pain syndrome, knee osteoarthritis and chronic low back pain. The AXS-05 on the other hand, treats resistant depression and agitation in patients with Alzheimer's disease. Both the products have passed the preclinical, Phase 1 and Phase 2 stages of development. |
